Table 4 Relative efficacy of Trichoderma parent and mutant isolates on percent recovery of lesion size
Isolates | Recovery of lesion size (%) | ||
|---|---|---|---|
2016–2017 | 2017–2018 | Total percent recovery | |
T2 Parent | 17.82 (24.94) | 26.46 (30.27) | 44.28 (41.60) |
T2 Mutant | 24.83 (29.30) | 27.17 (31.35) | 52.00 (46.11) |
T3 Parent | 18.07 (24.46) | 27.30 (31.23) | 45.37 (42.31) |
T3 Mutant | 25.84 (29.70) | 30.13 (33.08) | 55.97 (48.63) |
T4 Parent | 25.24 (30.10) | 30.41 (33.25) | 55.65 (48.30) |
T4 Mutant | 30.97 (33.76) | 40.29 (39.30) | 71.26 (57.75) |
T16 Parent | 31.45 (34.04) | 34.36 (35.70) | 65.82 (54.28) |
T16 Mutant | 36.71 37.21 | 46.10 (42.67) | 82.80 (68.44) |
T20 Parent | 36.18 (36.95) | 43.51 (41.21) | 79.69 (63.37) |
T20 Mutant | 44.45 (41.79) | 51.38 (45.77) | 95.67 (75.81) |
T21 Parent | 18.16 (23.62) | 21.63 (27.46) | 39.79 (38.87) |
T21 Mutant | 24.07 (28.73) | 26.71 (31.35) | 50.79 (45.43) |
T25 Parent | 20.77 (26.93) | 27.97 (31.84) | 48.74 (44.26) |
T25 Mutant | 26.87 (31.01) | 32.85 (34.74) | 59.71 (50.68) |
T.viride* | 27.29 (41.47) | 29.31 (31.98) | 56.60 (48.86) |
T.harzianum* | 17.98 (25.07) | 20.07 (26.59) | 38.05 (38.04) |
Metalaxyl-M+Mancozeb* | 35.44 (36.43) | 37.35 (37.63) | 72.80 (58.78) |
Control | (-)16.50 (23.64) | (-)23.41 (23.40) | (-)39.91 (39.11) |
CD (p ≤ 0.05) | 10.29 | 8.90 | 11.66 |